The Overview of Japanese CMO/CDMO Market-Ver2018
SKU:
$1,450.00
$1,450.00
per item
- Summary
- Definition of CMO/CDMO
- Laws and Regulations Related to CMOs
- Main Industry Group
- CMO Market Scale
- CMO Market Share
- Main CMOs
- Nipro Pharma
- Bushu Pharmaceuticals
- Teikoku Seiyaku
- CMIC CMO
- Catalent Japan
- Patheon
- Saltigo/Lanxess
- Other CMOs
- Outsourcing Trend from Pharma
- Trend of pharmas’ selling/closing Factories
- Market Entry from Generic Firms
- Market Entry from Drug makers
- OEM? CMO?
- CMO is profitable enough?
- Why non-Japanese CDMO have had low presence in Japan?
- Shift to biopharmaceuticals
- Future Prospects
The CMO market in 2016 was approximately 365 billion Yen, with 3% increase from the previous year.
While most of products outsourced from pharma are long listed drugs, we also see expanding demands for new drugs, investigational products, and generics these days.
Currently, 30% of pharmaceutical productions seem to be outsourced to 3rd parties such as CMO.
Japanese CMOs remain competitive, with local capability and facilities. Non-Japanese CMOs will continue to struggle, but the emergence of biopharmaceuticals will become a great opportunity to increase their presence to Japanese customers.
On the other hand, we are seeing increasing market erosion from generic companies into CMO business. As they have larger advantage with regards to customer base and capability, we expect generic companies will become the game changers.
As a whole, we expect that the market will grow very slightly, or even remain flat for several years. In the mid-term, we anticipate the convergence into large size of CMOs through M&As, and improved presence from non-Japanese CMOs.
While most of products outsourced from pharma are long listed drugs, we also see expanding demands for new drugs, investigational products, and generics these days.
Currently, 30% of pharmaceutical productions seem to be outsourced to 3rd parties such as CMO.
Japanese CMOs remain competitive, with local capability and facilities. Non-Japanese CMOs will continue to struggle, but the emergence of biopharmaceuticals will become a great opportunity to increase their presence to Japanese customers.
On the other hand, we are seeing increasing market erosion from generic companies into CMO business. As they have larger advantage with regards to customer base and capability, we expect generic companies will become the game changers.
As a whole, we expect that the market will grow very slightly, or even remain flat for several years. In the mid-term, we anticipate the convergence into large size of CMOs through M&As, and improved presence from non-Japanese CMOs.